Regulation of YAP through an Akt-dependent process by 3, 3'-diindolylmethane in human colon cancer cells

Li,Xiu  Juan; Leem,Sun-Hee; Park,Man  Hee; Kim,Soo  Mi

doi:10.3892/ijo.2013.2121

Regulation of YAP through an Akt-dependent process by 3, 3'-diindolylmethane in human colon cancer cells

Authors:
- Xiu Juan Li
- Sun-Hee Leem
- Man Hee Park
- Soo Mi Kim
View Affiliations

Affiliations: Department of Physiology, Institute for Medical Sciences, Chonbuk National University Medical School, Jeonju, Republic of Korea, Department of Biological Science, Dong-A University, Busan, Republic of Korea, Catholic University of Pusan, Busan, Republic of Korea
Published online on: October 3, 2013 https://doi.org/10.3892/ijo.2013.2121
Pages: 1992-1998

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cancer development is a complex process governed by the interaction of several signaling pathways. The Hippo and PI3K/Akt pathways have been shown to play a critical role in controlling tissue growth involved in the regulation of cell proliferation. 3, 3'-diindolylmethane (DIM) is a natural compound that selectively kills cancer cells without causing toxicity to normal cells. This study aims to investigate whether DIM has an effect on the Hippo signaling pathway mediated via the PI3K/Akt signaling pathway in colon cancer cells. Our study provides new insights into the mechanisms of crosstalk between Hippo signaling and the Akt pathway controlling cell proliferation by PI3K inhibitor and DIM treatment in colon cancer cells. DIM strongly potentiates the lethality of LY294002 in HCT116 cells and inhibits proliferation of colon cancer cells via inactivation of Akt and YAP. Thus, DIM has dramatic therapeutic effects when it is combined with the PI3K inhibitor in the treatment of colon cancer cells. These findings highlight the potential usefulness of DIM and can help develop therapeutic strategies for the prevention and treatment of colon cancer.

View Figures

View References

1.	Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249. 2009. View Article : Google Scholar
2.	Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
3.	Leystra AA, Deming DA, Zahm CD, et al: Mice expressing activated PI3K rapidly develop advanced colon cancer. Cancer Res. 72:2931–2936. 2012. View Article : Google Scholar : PubMed/NCBI
4.	Vivanco I and Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2:489–501. 2002. View Article : Google Scholar : PubMed/NCBI
5.	Pal I and Mandal M: PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes. Acta Pharmacol Sin. 33:1441–1458. 2012. View Article : Google Scholar : PubMed/NCBI
6.	Oldham S and Hafen E: Insulin/IGF and target of rapamycin signaling: a TOR de force in growth control. Trends Cell Biol. 13:79–85. 2003. View Article : Google Scholar : PubMed/NCBI
7.	Hietakangas V and Cohen SM: Regulation of tissue growth through nutrient sensing. Annu Rev Genet. 43:389–410. 2009. View Article : Google Scholar : PubMed/NCBI
8.	Michlig S, Harris M, Loffing J, Rossier BC and Firsov D: Progesterone down-regulates the open probability of the amiloride-sensitive epithelial sodium channel via a Nedd4-2-dependent mechanism. J Biol Chem. 280:38264–38270. 2005. View Article : Google Scholar : PubMed/NCBI
9.	Saif MW and Chu E: Biology of colorectal cancer. Cancer J. 16:196–201. 2010. View Article : Google Scholar
10.	Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I and Kerr D: Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer. 9:489–499. 2009. View Article : Google Scholar : PubMed/NCBI
11.	Tenbaum SP, Ordonez-Moran P, Puig I, et al: beta-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat Med. 18:892–901. 2012. View Article : Google Scholar : PubMed/NCBI
12.	Abdul-Ghani R, Serra V, Gyorffy B, et al: The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1. Oncogene. 25:1743–1752. 2006. View Article : Google Scholar : PubMed/NCBI
13.	Martini M, Ciraolo E, Gulluni F and Hirsch E: Targeting PI3K in cancer: any good news? Front Oncol. 3:1082013. View Article : Google Scholar : PubMed/NCBI
14.	Vlahos CJ, Matter WF, Hui KY and Brown RF: A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem. 269:5241–5248. 1994.PubMed/NCBI
15.	Tumaneng K, Russell RC and Guan KL: Organ size control by Hippo and TOR pathways. Curr Biol. 22:R368–R379. 2012. View Article : Google Scholar : PubMed/NCBI
16.	Steinhardt AA, Gayyed MF, Klein AP, et al: Expression of Yes-associated protein in common solid tumors. Hum Pathol. 39:1582–1589. 2008. View Article : Google Scholar : PubMed/NCBI
17.	Konsavage WM Jr, Kyler SL, Rennoll SA, Jin G and Yochum GS: Wnt/beta-catenin signaling regulates Yes-associated protein (YAP) gene expression in colorectal carcinoma cells. J Biol Chem. 287:11730–11739. 2012. View Article : Google Scholar : PubMed/NCBI
18.	Avruch J, Zhou D and Bardeesy N: YAP oncogene overexpression supercharges colon cancer proliferation. Cell Cycle. 11:1090–1096. 2012. View Article : Google Scholar : PubMed/NCBI
19.	Zhou D, Zhang Y, Wu H, et al: Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance. Proc Natl Acad Sci USA. 108:E1312–1320. 2011. View Article : Google Scholar : PubMed/NCBI
20.	Yuen HF, McCrudden CM, Huang YH, et al: TAZ expression as a prognostic indicator in colorectal cancer. PloS One. 8:e542112013. View Article : Google Scholar : PubMed/NCBI
21.	Kim SJ, Chung MJ, Kim JS, et al: Deciphering the role of paclitaxel in the SKGT4 human esophageal adenocarcinoma cell line. Int J Oncol. 39:1587–1591. 2011.PubMed/NCBI
22.	Kim SJ, Lee JS and Kim SM: 3,3′-Diindolylmethane suppresses growth of human esophageal squamous cancer cells by G1 cell cycle arrest. Oncol Rep. 27:1669–1673. 2012.
23.	Eisen MB, Spellman PT, Brown PO and Botstein D: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA. 95:14863–14868. 1998. View Article : Google Scholar : PubMed/NCBI
24.	Ahmad A, Ali S, Ahmed A, et al: 3, 3′-Diindolylmethane enhances the effectiveness of herceptin against HER-2/neu-expressing breast cancer cells. PloS One. 8:e546572013.
25.	Bhatnagar N, Li X, Chen Y, Zhou X, Garrett SH and Guo B: 3,3′-diindolylmethane enhances the efficacy of butyrate in colon cancer prevention through down-regulation of survivin. Cancer Prev Res. 2:581–589. 2009.
26.	Kim YH, Kwon HS, Kim DH, et al: 3,3′-diindolylmethane attenuates colonic inflammation and tumorigenesis in mice. Inflamm Bowel Dis. 15:1164–1173. 2009.
27.	Pappa G, Strathmann J, Lowinger M, Bartsch H and Gerhauser C: Quantitative combination effects between sulforaphane and 3,3′-diindolylmethane on proliferation of human colon cancer cells in vitro. Carcinogenesis. 28:1471–1477. 2007.
28.	Li Y, Li X and Guo B: Chemopreventive agent 3,3′-diindolylmethane selectively induces proteasomal degradation of class I histone deacetylases. Cancer Res. 70:646–654. 2010.
29.	Choi HJ, Lim do Y and Park JH: Induction of G1 and G2/M cell cycle arrests by the dietary compound 3,3′-diindolylmethane in HT-29 human colon cancer cells. BMC Gastroenterol. 9:392009.PubMed/NCBI
30.	Gao N, Cheng S, Budhraja A, et al: 3,3′-Diindolylmethane exhibits antileukemic activity in vitro and in vivo through a Akt-dependent process. PloS One. 7:e317832012.
31.	Kim AH, Khursigara G, Sun X, Franke TF and Chao MV: Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol Cellular Biol. 21:893–901. 2001. View Article : Google Scholar : PubMed/NCBI
32.	Alessi DR, Andjelkovic M, Caudwell B, et al: Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 15:6541–6551. 1996.PubMed/NCBI
33.	Harvey KF, Zhang X and Thomas DM: The Hippo pathway and human cancer. Nat Rev Cancer. 13:246–257. 2013. View Article : Google Scholar : PubMed/NCBI
34.	Halder G and Johnson RL: Hippo signaling: growth control and beyond. Development. 138:9–22. 2011. View Article : Google Scholar : PubMed/NCBI
35.	Harvey K and Tapon N: The Salvador-Warts-Hippo pathway - an emerging tumour-suppressor network. Nat Rev Cancer. 7:182–191. 2007. View Article : Google Scholar : PubMed/NCBI
36.	Lu L, Li Y, Kim SM, et al: Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci USA. 107:1437–1442. 2010. View Article : Google Scholar : PubMed/NCBI
37.	Camargo FD, Gokhale S, Johnnidis JB, et al: YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol. 17:2054–2060. 2007. View Article : Google Scholar : PubMed/NCBI
38.	Cai J, Zhang N, Zheng Y, de Wilde RF, Maitra A and Pan D: The Hippo signaling pathway restricts the oncogenic potential of an intestinal regeneration program. Genes Dev. 24:2383–2388. 2010. View Article : Google Scholar : PubMed/NCBI
39.	Ye X, Deng Y and Lai ZC: Akt is negatively regulated by Hippo signaling for growth inhibition in Drosophila. Dev Biol. 369:115–123. 2012. View Article : Google Scholar : PubMed/NCBI
40.	Cinar B, Fang PK, Lutchman M, et al: The pro-apoptotic kinase Mst1 and its caspase cleavage products are direct inhibitors of Akt1. EMBO J. 26:4523–4534. 2007. View Article : Google Scholar : PubMed/NCBI